Fourth Amendment to Collaboration Research, Development and License Agreements



 Exhibit 10.2 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange Commission. 

Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 240.24b-2. 
 FOURTH AMENDMENT TO 
 COLLABORATIVE RESEARCH, DEVELOPMENT 
 AND LICENSE AGREEMENTS 
 THIS FOURTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS
(the “Fourth Amendment”) is entered into as of April 22, 2009 (the “Fourth Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a
Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC, a Delaware limited liability company
(“Allergan”) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.

 RECITALS 
 WHEREAS, the parties previously entered into that certain Collaborative Research, Development and License Agreement, dated September 24, 1997 (as amended by the First Amendment, the Second
Amendment and the Third Amendment described below, the “1997 Agreement”), pursuant to which the parties conducted collaborative research regarding, among other things, receptor selective compounds with the goal of
establishing drug discovery programs related to such receptor selective compounds; 
 WHEREAS, the parties previously
entered into that certain Collaborative Research, Development and License Agreement, dated July 26, 1999 (the “1999 Agreement”), pursuant to which the parties conducted collaborative research regarding [...***...]
muscarinic compounds for the treatment or prevention of ocular disease; 
 WHEREAS, the 1997 Agreement
was first amended on March 27, 2003 (the “First Amendment”) to continue the collaboration under the 1997 Agreement with respect to alpha adrenergic receptors and on the same date the parties entered into a new
Collaborative Research, Development and License Agreement (the “2003 Agreement”) regarding ACADIA’s chemical-genomics assets; 
 WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on February 28, 2006 (the “Second Amendment”) to continue the collaboration under the
1997 Agreement and the 2003 Agreement with respect to alpha adrenergic receptors and to continue to collaborate on other receptor selective compounds included in ACADIA’s chemical-genomics assets; 
 WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on March 3, 2008 (the “Third
Amendment”) to continue the collaboration under the 1997 Agreement and the 2003 Agreement with respect to alpha adrenergic receptors and to continue to collaborate on muscarinic compounds for eye-care applications; 
 WHEREAS, the periods for research to be done pursuant to the 1997 Agreement and the 2003 Agreement (together, the
“Agreements”) will expire on March 27, 2009; 
  


					
		  	1	  	***Confidential Treatment Requested









 WHEREAS, the parties wish to expand their collaboration on [...***...]
muscarinic selective compounds for eye-care indications on the terms set forth below; and 
 WHEREAS,
the parties may wish to collaborate on muscarinic selective compounds for eye care indications or on other selective compounds included in ACADIA’s chemical-genomics assets pursuant to the 2003 Agreement and on the terms set forth below.

 NOW THEREFORE, in consideration of the foregoing and the covenants and premises contained in this
Fourth Amendment, the parties hereby agree as follows: 
 1. Alpha Adrenergic Research Program. The parties’ research under the Agreements
on alpha adrenergic receptors (the “Alpha Adrenergic Research Program”) shall cease. The Joint Research Committee shall no longer manage or otherwise concern itself with matters relating to research on alpha adrenergic
receptors. The Research Term of the Agreements with respect to the Alpha Adrenergic Research Program expired as of March 27, 2009. Allergan shall retain all of its current exclusive licenses under Section 5.1 of the 1997 Agreement to the
ACADIA Technology in the Allergan Field as to alpha adrenergic receptors. For as long as Allergan is continuing to use commercially reasonable efforts to pursue research, development, marketing and/or sale of an Allergan Development Candidate or
Allergan Product that is biologically active against an alpha adrenergic receptor, ACADIA shall not, by itself or in collaboration with a third party, use the ACADIA Technology or the Collaboration Technology in the Allergan Field to research
compounds, whose primary biological activity is against an alpha adrenergic receptor. (Capitalized terms used in this paragraph that are not defined have the meaning given to them in the 1997 Agreement). 
 2. [...***...] Expansion Program. The parties have agreed on a pool of ten (10) compounds from ACADIA’s library of [...***...]
muscarinic selective compounds from which Allergan may chose a backup compound (the “[...***...] Expansion Program”). The current ten (10) compounds are listed on Exhibit A hereto (the
“Back-up Pool”). The Research Term of the Agreements with respect to the [...***...] Expansion Program shall be extended to cover the period beginning March 28, 2009 and ending March 27, 2010 (the
“Additional Extension Period”). During the Additional Extension Period, ACADIA will provide information on compounds included in the Back-up Pool for continued evaluation by the parties. Further, if directed by the JRC (as
defined below), ACADIA shall engage in the synthesis and evaluation of additional [...***...] muscarinic selective compounds. Allergan may remove and add compounds to the Back-up Pool from (a) ACADIA’s existing [...***...]
muscarinic selective compounds (i.e., those identified prior to the Additional Extension Period), upon mutual agreement of the parties, or (b) from new compounds synthesized at the direction of the JRC, so long as the total number of compounds
in the Back-up Pool does not exceed ten (10) at any given time. Allergan may select one compound from the Back-up Pool to be treated as a Collaboration Lead Compound (as defined in the 1999 Agreement and in addition to the compound based on
[...***...], which has been advanced by the parties pursuant to the 1999 Agreement) pursuant to the terms of the 1999 Agreement. Allergan shall use reasonable efforts to select a compound from the Back-up Pool to be treated as 

  


					
		  	2	  	***Confidential Treatment Requested









 
a second Collaboration Lead Compound prior to the end of the Additional Extension Period. Allergan’s right to so select a compound shall expire at the
end of the Additional Extension Period. Upon selecting a compound from the Back-up Pool to be treated as a Collaboration Lead Compound, Allergan shall be entitled to select another compound to add to the Back-up Pool from (a) ACADIA’s
existing [...***...] muscarinic selective compounds (i.e., those identified prior to the Additional Extension Period), upon mutual agreement of the parties, or (b) from compounds synthesized at the direction of the JRC during the
Additional Extension Period, so that Allergan retains ten (10) compounds within the Back-up Pool through the end of the Additional Extension Period. If Allergan selects a Back-up Pool compound to be treated as a Collaboration Lead Compound
during the Additional Extension Period, then until one year after the end of the Additional Extension Period, Allergan may exchange such Collaboration Lead Compound for a compound within the Back-up Pool, which will then be treated as a
Collaboration Lead Compound. Other than any such exchange, the Back-up Pool will not change after the end of the Additional Extension Period. Allergan shall have no rights to the compounds remaining in the Back-up Pool, or those compounds
synthesized at the direction of the JRC that are not in the Back-up Pool, on the one-year anniversary of the end of the Additional Extension Period. 
 3.
Additional Extension Program. During the Additional Extension Period, ACADIA, if directed by the JRC, will undertake discovery efforts to identify new compounds that meet mutually acceptable selection criteria for muscarinic selective
compounds for [...***...]. These efforts will include mining of ACADIA’s library of muscarinic compounds, re-screening where desired, in vitro pharmacology/ characterization, and supporting synthesis to enable selection of potential
compounds by Allergan for in vivo pharmacology and potential development (the “Additional Extension Program”). If the Additional Extension Program is commenced, then muscarinic selective compounds identified pursuant to the
Additional Extension Program may be designated by Allergan as a Selected Target/Chemistry (as defined in the 2003 Agreement) in accordance with Section 5.1 of the 2003 Agreement; provided that the right to exercise the Option (as defined in the
2003 Agreement) for such Selected Target/Chemistry shall expire on March 27, 2010, notwithstanding the Option Period definition in Section 1.45 of the 2003 Agreement. 
 4. FTE Funding. Research funding during the Additional Extension Period shall be [...***...]. During the Additional Extension Period, Allergan shall fund a minimum of [...***...], and up to a
maximum of [...***...]. The Joint Research Committee (the “JRC”) shall determine the work to be done under the [...***...] Expansion Program, including the appropriate number of FTEs for such level of work. During
the Additional Extension Period, Allergan, with the consent of the JRC, also may elect to pursue the Additional Extension Program. If Allergan elects to pursue the Additional Extension Program, the JRC shall determine the number of ACADIA FTEs
required for such program. The allocation of FTEs between the Additional Extension Program, if any, and the [...***...] Expansion Program shall be decided by the JRC, provided however in the event that the parties do not agree on such
allocation, notwithstanding Section 15.2 of the 2003 Agreement, [...***...]. 
  


					
		  	3	  	***Confidential Treatment Requested









 5. Research Coordinators. Allergan and ACADIA shall each appoint an individual to act as the research
coordinator for such party (each, a “Research Manager”). The Research Managers shall be the primary contact for the parties regarding the activities contemplated by this Fourth Amendment and shall facilitate all such
activities hereunder. The initial Research Manager for Allergan shall be Daniel Gil and the initial Research Manager for ACADIA shall be Ethan Burstein. Each party may replace its Research Manager with another individual at any time with prior
written notice to the other party. Each Research Manager who is not otherwise a member of the JRC shall be permitted to attend meetings of the JRC. 
 6.
Patent Costs. In the event that Allergan selects a Back-up Pool compound to be treated as a Collaboration Lead Compound pursuant to Section 2 above, then Allergan shall reimburse ACADIA for [...***...] of all reasonable out of pocket
legal expenses incurred by ACADIA that are associated with the filing and prosecuting of (i) all Collaboration Patents having one or more claims covering such compound, and (ii) any ACADIA Patents having one or more claims covering such
compound. (Capitalized terms used in this paragraph that are not defined have the meaning given to such terms in the 1999 Agreement). 
 7.
Bankruptcy. All rights and licenses granted under the 1997 Agreement, the 1999 Agreement, the 2003 Agreement, and any amendments to those agreements will be considered for purposes of Section 365(n) of 11 U.S.C. (the
“Bankruptcy Code”) licenses of rights to “intellectual property” as defined under Section 101(56) of the Bankruptcy Code. The parties agree that a licensee of such rights under those agreements will retain and
may fully exercise all of its rights and elections under the Bankruptcy Code. In the event that a licensor seeks or is involuntarily placed under the protection of the Bankruptcy Code, and the trustee in bankruptcy rejects any of those agreements,
the licensee hereby elects, pursuant to Section 365(n), to retain all rights granted to it under those agreements to the extent permitted by law. 
 8. Full Force and Effect. Except as it may specifically be amended by this Fourth Amendment, each of the 1997 Agreement, the 1999 Agreement, the 2003 Agreement, and any amendments to those agreements, shall remain in full force and
effect. If there is any inconsistency or conflict between any provision in this Fourth Amendment and any of the foregoing agreements, as amended to date, the provision in this Fourth Amendment shall control. 
 9. Miscellaneous. This Fourth Amendment may be signed in counterparts, each of which shall be deemed an original, all of which taken together shall be deemed one
instrument. This Fourth Amendment shall be governed by the laws of the State of California as such laws are applied to contracts entered into or to be performed entirely within such state. 
  


					
		  	4	  	***Confidential Treatment Requested









 IN WITNESS WHEREOF, the parties hereto have duly executed this
FOURTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS. 

 

									
	ACADIA PHARMACEUTICALS INC.	 		 	 ALLERGAN SALES, LLC, a Delaware limited
 liability company, a successor in interest of

	By:	 	 /s/    Uli Hacksell
	 		 	            VISION PHARMACEUTICALS L.P.,
	Name:	 	Uli Hacksell	 		 	A Texas limited partnership, dba Allergan,
	Title:	 	CEO	 		 	by Allergan General, Inc.,
		 		 		 	its general partner
					
		 		 		 	By:	 	 /s/    David M. Lawrence

		 		 		 	Name:	 	David M. Lawrence
		 		 		 	Title:	 	Vice President
				
		 		 		 	Guarantee of performance by:
				
		 		 		 	ALLERGAN, INC.
					
		 		 		 	By:	 	 /s/    Scott M. Whitcup

		 		 		 	Name:	 	Scott M. Whitcup, M.D.
		 		 		 	Title:	 	 Executive Vice President,
 Research and
Development


  

 5 








 Exhibit A 
 List of Compounds Currently in Back-up Pool 
 [...***...] 
  


					
		  	6	  	***Confidential Treatment Requested